Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05561803
Other study ID # Radiodermatitistalita30
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date April 8, 2024
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source University of Nove de Julho
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It is estimated that there will be 670,000 new cases of cancer worldwide in 2020-2022 and it is known that the most commonly instituted treatments in cancer are chemotherapy, radiotherapy and surgery. However, these treatments have undesirable side effects, such as Radiodermatitis after Radiotherapy (RD). In fact, the prevalence of possible side effects after radiotherapy is estimated to be 80 to 90%. Radiotherapy complications are associated with a negative impact on patients' quality of life and few supportive measures are available for such complications. Thus, the management of these side effects has been studied in the literature until the present day. On the other hand, Photobiomodulation (PBM) has an important role in wound repair and tissue regeneration, as it influences the different phases of lesion resolution, including the inflammatory phase, the proliferative phase and the remodeling phase. Thus, the aim of this study is to report a case series of Cancer Patients diagnosed with radiotherapy-induced acute radiodermatitis on Palliative Care, treated with PBM. This is a case series report and the study data will be extracted from the medical records of forty cancer patients with grade 2 or 3 RD followed up from September 2023 at the Laser Therapy Outpatient Clinic in a Universitary Hospital. The outcomes are the size of the lesion, the presence of pain assessed by the Visual Analogue Scale (VAS), the Portuguese Version of WHOQOL BREF Scale and the RTOG Scale (Radiation Therapy Oncology Group Scale) to assess the degree of Radiodermatitis before and after PBM therapy. The data will be subjected to a statistical analysis and will be discussed. Data with positive or negative results will be reported.


Description:

It is estimated that there will be 670,000 new cases of cancer worldwide in 2020-2022 and it is known that the most commonly instituted treatments in cancer are chemotherapy, radiotherapy and surgery. However, these treatments have undesirable side effects, such as Radiodermatitis after Radiotherapy (RD). In fact, the prevalence of possible side effects after radiotherapy is estimated to be 80 to 90%. Radiotherapy complications are associated with a negative impact on patients' quality of life and few supportive measures are available for such complications. Thus, the management of these side effects has been studied in the literature until the present day. On the other hand, Photobiomodulation (PBM) has an important role in wound repair and tissue regeneration, as it influences the different phases of lesion resolution, including the inflammatory phase, the proliferative phase and the remodeling phase. Thus, the aim of this study is to report a case series of forty cancer patients on palliative care diagnosed with radiotherapy-induced acute radiodermatitis Grade 2or 3, treated with PBM. This is a case series report and the study data will be extracted from the medical records of patients with grade 2 or 3 RD followed up from September 2023 at the Laser Therapy Outpatient Clinic in a Universitary Hospital. The outcomes are the size of the lesion, the presence of pain assessed by the Visual Analogue Scale (VAS), the Portuguese Version of WHOQOL BREF Scale and the RTOG Scale (Radiation Therapy Oncology Group Scale) to assess the degree of Radiodermatitis before and after PBM therapy. The assessment will be done pre-treatment, weekly during PBM therapy and post-treatment. The PBM therapy are focal low-level laser therapy, 1 to 3 Joules per point, depending on the degree of pain, wavelength 633 to 685 nm, transcutaneously on the surface of the tissue injured by radiotherapy, three times a week during radiotherapy treatment and two more applications after the end of radiotherapy The data will be subjected to a statistical analysis and will be discussed. Data with positive or negative results will be reported.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2024
Est. primary completion date July 31, 2024
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Older than 18 years; 2. Patients with any oncological etiology; 3. With the presence of established radiodermatitis RTOG II or III; 4. Patients who are undergoing palliative oncological care and RD standard treatment; 5. Patients who do not present clinical signs of another pathology that justifies the presence of the skin lesion; 6. Patients do not have local skin infection Exclusion Criteria: - Critical clinical states; - Patients with skin lesions of another cause even when undergoing RT; - Patients referred to the laser clinic for the prevention of radiodermatitis without the active RD lesion. - Patients who have used another photobiomodulation therapy protocol foresaw injury not related to the study. - All contraindications already defined in the routine referral to the outpatient clinic (patients who have an active tumor at the site to be irradiated; individuals with a history of photosensitivity to photonic or light therapy; patients who have undiagnosed lesions in the treatment region; patients using topical photosensitizing medications or creams; cognitive, psychiatric or neurological changes that prevent the free understanding of the PBM therapy

Study Design


Intervention

Radiation:
Photobiomodulation Therapy
Focal low-level laser therapy, Red Laser (wavelength 633 nm to 685 nm), or Infrared Laser Laser (wavelength 780 nm to 830 nm), with a low-intensity laser equipment of 100 mW and a cross-sectional area of the device beam of 0.0434 cm². The parameters are 1 to 3 J per point, with equidistant points of 1.5 to 2 cm, covering the entire length of the open lesion. Therapy is carried out every 48 hours until the total wound healing, regardless of the number of sessions required.

Locations

Country Name City State
Brazil Universidade Nove de Julho / Post-Graduate program Biophotonics Applied to Health Sciences São Paulo Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Nove de Julho

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Toxicity criteria of the Radiation Therapy Oncology Group Scale (RTOG Scale) RTOG scale assess the degree and intensity of RD. It identifies degree 0 (no reaction), 1 (faint erythema, dry desquamation, epilation, diminished sweating), 2 (moderate, brisk erythema, exudative dermatitis in plaques and moderate edema), 3 (exudative dermatitis, besides cutaneous folds and intense edema) and 4 (ulceration, hemorrhage, necrosis). Change from Baseline at 14 days after end of radiotherapy treatment]
Primary Lesion Size Evaluation of lesion measurement in centimeters Change from Baseline at 14 days after end of radiotherapy treatment]
Primary Portuguese version of The World Health Organization Quality of Life Scale (WHOQOL-BREF) The WHOWOL BREF scale assess multidimensional aspects of geral quality of life of patients. The multidimensional scale is composed by 26 items, classified from 1 to 5 according to the intensity of the symptom presented. The global score is calculated by adding up all the items as well as the score for each domain is evaluated adding it individually for each item, which can range from 0 to 130, Change from Baseline at 14 days after end of radiotherapy treatment]
Secondary Visual Analog Scale of Pain VAS Scale assess the pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Change from Baseline at 14 days after end of radiotherapy treatment]
See also
  Status Clinical Trial Phase
Completed NCT04673760 - The PROAKTIV Study N/A
Completed NCT03520023 - Critical Care and Palliative Care Medicine Together in the ICU N/A
Completed NCT01990742 - Improving Palliative Care Through Teamwork N/A
Not yet recruiting NCT05434208 - Effects of Nurse-led Telephone Based Service for Early Palliative Care (PALTEL) N/A
Not yet recruiting NCT03267706 - Introducing the Palliative Care Comprehensive Tool in Family Medicine N/A
Completed NCT02845817 - Requests for Euthanasia and Assisted Suicide N/A
Recruiting NCT02778347 - Development and Validation of a Comprehensive Standardised Clinical Assessment Tool for Patient Needs N/A
Completed NCT01934413 - Technology-enhanced Transitional Care for Rural Palliative Care Patients: A Pilot Study N/A
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Recruiting NCT01170000 - Timely End-of-Life Communication to Parents of Children With Brain Tumors N/A
Recruiting NCT04052074 - Complementary Therapy in Home Palliative Care Patients and Their Caregivers N/A
Recruiting NCT05935540 - ACP-Family Programme for Palliative Care Patients and Their Family Member N/A
Active, not recruiting NCT02689375 - A Prospective, Open Label, Pilot Study of Patient OutcoMes Following Successful TriAl of High Frequency SpInal CorD Stimulation at 10kHz (HF10™) Leading to Permanent Implant Compared to Trial Failure and Standard CarE for the TreatmeNt of Persistent Low BACK Pain of Neuropathic Origin N/A
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Completed NCT06140004 - Home-Based Palliative Care Impact on Providers
Completed NCT04333719 - Prevalence of Deep Sedation in Terminal Palliative Phase
Recruiting NCT03286127 - Palliative Outcome Evaluation Muenster I
Completed NCT06211816 - Efficacy of End-of-life Communication Strategies on Nurses in the Intensive Care Unit N/A
Completed NCT04857060 - Palliative Care Educator N/A
Completed NCT04491110 - Intervention to Improve Quality of Sleep of Palliative Patient Carers in the Community: Clinical Trial N/A